Int J Gynecol Pathol. 2021 Mar 1;40(Suppl 1):S92-S101. doi: 10.1097/PGP.0000000000000758.
The International Federation of Gynecology and Obstetrics (FIGO) updated its staging system for cervical cancer in 2018 with changes that affect size criteria for early stage disease, as well as including pathology and radiology in addition to clinical assessment to be used in staging. Lymph node involvement was also included in the staging system. In early stage disease, pathologic findings are crucial in determining stage, which in turn determine treatment and prognosis for the patient. Therefore, it is imperative that there are unified and consistent methods and recommendations for assessing and reporting pathologic parameters for accurate staging. We describe the changes in the revised FIGO staging scheme and discuss controversial issues in cervical cancer staging from a pathologic perspective. We also provide practical recommendations regarding these parameters based on literature review and/or expert opinion/consensus.
国际妇产科联盟（FIGO）于 2018 年更新了宫颈癌分期系统，其中包括对早期疾病大小标准的改变，以及将病理和放射学纳入分期中，除了临床评估。淋巴结受累也被纳入分期系统。在早期疾病中，病理发现对确定分期至关重要，而分期又决定了患者的治疗和预后。因此，评估和报告病理参数以进行准确分期的方法和建议必须是统一和一致的。我们描述了修订后的 FIGO 分期方案的变化，并从病理角度讨论了宫颈癌分期中的争议问题。我们还根据文献回顾和/或专家意见/共识提供了关于这些参数的实用建议。
